MedTrace Logo

A Study of DISC-3405 in Healthy Volunteers

NCT06050915 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-12-18

No results posted yet for this study

Summary

This phase 1 study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of DISC-3405 in adult male and female healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

DRUG

DISC-3405

DISC-3405 is administered as a single dose IV infusion or subcutaneous injection

DRUG

DISC-3405

DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection

DRUG

Placebo

Placebo is administered as a single dose IV infusion or subcutaneous injection

DRUG

Placebo

Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection

Sponsors & Collaborators

  • Disc Medicine, Inc

    lead INDUSTRY

Principal Investigators

  • Will Savage, MD PhD · Disc Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2024-07-09
Completion
2024-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06050915 on ClinicalTrials.gov